The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Learn about the uses, dosage, price and more for Nucala (mepolizumab), a prescription injection that treats asthma and other conditions in adults and some children.

Nucala stands out as the only approved biologic that has been specifically evaluated in patients whose eosinophilic phenotype is defined by a blood eosinophil count (BEC) threshold as low as ≥ ...

GSK (NYSE:GSK) announced Friday that its asthma therapy Nucala (mepolizumab) reached the main goal in a Phase 3 trial for patients with chronic obstructive pulmonary disease (COPD), a common lung ...

Nucala's approval was also bolstered by older results from the late-stage Metrex study, which pitted the drug against placebo both in COPD patients with an eosinophilic phenotype and those without.

Nucala is a type of medicine called a “specialty” medicine. This means that you can only get it from a specialty pharmacy, which may need to ship the medicine to you.

Nucala has been developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation. Itis currently approved for use in Europe across four IL-5 mediated ...

Nucala is approved by the FDA for five indications - severe asthma, EGPA, severe eosinophilic asthma, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps.

British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or smoker's lungs.